Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia

Advances in the biological understanding of chronic myeloid leukemia (CML) and therapy with tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for patients with CML. At the 20th Congress of the European Hematology Association (EHA), Gianantonio Rosti, MD, of the University of Bologna, Bologna, Italy, considers the feasibility of first- and second-generation TKI treatment discontinuation in patients with CML, as well as how monitoring treatment responses and patient advocacy can impact outcomes.